NASDAQ:PODDInsulet Stock Price, Forecast & News

Insulet's stock was trading at $172.11 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, PODD shares have increased by 26.5% and is now trading at $217.73.
View which stocks have been most impacted by Coronavirus.

20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Insulet in the last year. There are currently 1 sell rating, 11 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Insulet.

Insulet is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Insulet.

Insulet Co. (NASDAQ:PODD) issued its quarterly earnings results on Thursday, August, 6th. The medical instruments supplier reported $0.22 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.01) by $0.23. The medical instruments supplier had revenue of $226.30 million for the quarter, compared to analyst estimates of $212.41 million. Insulet had a return on equity of 24.43% and a net margin of 2.20%. Insulet's revenue for the quarter was up 27.8% compared to the same quarter last year. During the same quarter last year, the business posted $0.02 EPS.
View Insulet's earnings history.

Insulet issued an update on its FY 2020 After-Hours earnings guidance on Thursday, August, 6th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $863.694-878.458 million, compared to the consensus revenue estimate of $849.76 million.

20 brokerages have issued 12-month target prices for Insulet's stock. Their forecasts range from $165.00 to $260.00. On average, they expect Insulet's stock price to reach $223.00 in the next year. This suggests a possible upside of 2.4% from the stock's current price.
View analysts' price targets for Insulet.

News headlines about PODD stock have trended very positive recently, according to InfoTrie Sentiment. The research group identifies positive and negative press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Insulet earned a news sentiment score of 4.0 on InfoTrie's scale. They also gave headlines about the medical instruments supplier a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future.
View the latest news about Insulet.

Some companies that are related to Insulet include Abbott Laboratories (ABT), Medtronic (MDT), Intuitive Surgical (ISRG), Stryker (SYK), Becton Dickinson and (BDX), Boston Scientific (BSX), Edwards Lifesciences (EW), DexCom (DXCM), Baxter International (BAX), IDEXX Laboratories (IDXX), ResMed (RMD), Hologic (HOLX), Teleflex (TFX), Varian Medical Systems (VAR) and ABIOMED (ABMD).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Insulet investors own include DexCom (DXCM), NVIDIA (NVDA), Alibaba Group (BABA), Netflix (NFLX), Veeva Systems (VEEV), Adobe (ADBE), salesforce.com (CRM), Shopify (SHOP), Teladoc Health (TDOC) and Alteryx (AYX).

Insulet trades on the NASDAQ under the ticker symbol "PODD."

Insulet's stock is owned by many different retail and institutional investors. Top institutional investors include Mint Tower Capital Management B.V. (12.74%), Frontier Capital Management Co. LLC (1.29%), Victory Capital Management Inc. (0.66%), Sumitomo Mitsui Trust Holdings Inc. (0.49%), KAMES CAPITAL plc (0.48%) and Swiss National Bank (0.39%). Company insiders that own Insulet stock include Aiman Abdel-Malek, Charles Alpuche, Corinne H Nevinny, David A Lemoine, David Colleran, Eric Benjamin, John A Fallon, Michael L Levitz, Michael P Spears, Sally Crawford and Shacey Petrovic.
View institutional ownership trends for Insulet.

PODD stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Russell Investments Group Ltd., Chartwell Investment Partners LLC, First Trust Advisors LP, GW&K Investment Management LLC, KAMES CAPITAL plc, Sumitomo Mitsui Trust Holdings Inc., and New York State Common Retirement Fund. Company insiders that have sold Insulet company stock in the last year include Corinne H Nevinny, David A Lemoine, Eric Benjamin, John A Fallon, Michael P Spears, and Shacey Petrovic.
View insider buying and selling activity for Insulet.

PODD stock was acquired by a variety of institutional investors in the last quarter, including Mint Tower Capital Management B.V., SeaTown Holdings Pte. Ltd., Jag Capital Management LLC, Jennison Associates LLC, Frontier Capital Management Co. LLC, Granite Investment Partners LLC, Columbus Circle Investors, and State of Alaska Department of Revenue.
View insider buying and selling activity for Insulet.

Shares of PODD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of PODD stock can currently be purchased for approximately $217.73.

Insulet has a market capitalization of $13.73 billion and generates $738.20 million in revenue each year. The medical instruments supplier earns $11.60 million in net income (profit) each year or $0.19 on an earnings per share basis. Insulet employs 1,350 workers across the globe.

The official website for Insulet is www.insulet.com.

Insulet's mailing address is 100 NAGOG PARK, ACTON MA, 01720. The medical instruments supplier can be reached via phone at 978-600-7000 or via email at [email protected]